148 related articles for article (PubMed ID: 11115719)
1. A comparison of two commercial recombinant vaccines for hepatitis B in adolescents.
Leroux-Roels G; Abraham B; Fourneau M; De Clercq N; Safary A
Vaccine; 2000 Nov; 19(7-8):937-42. PubMed ID: 11115719
[TBL] [Abstract][Full Text] [Related]
2. Safety and immunogenicity of a modified process hepatitis B vaccine in healthy adults ≥50 years.
Gilbert CL; Klopfer SO; Martin JC; Schödel FP; Bhuyan PK
Hum Vaccin; 2011 Dec; 7(12):1336-42. PubMed ID: 22185811
[TBL] [Abstract][Full Text] [Related]
3. Immunogenicity and reactogenicity of two recombinant hepatitis B vaccines in healthy adolescents on two-dose schedule.
Chen CC; Chang MH; Lee HC; Twu SJ; Safary A
Acta Paediatr Taiwan; 1999; 40(3):157-60. PubMed ID: 10910606
[TBL] [Abstract][Full Text] [Related]
4. Multicenter study on the immunogenicity and safety of two recombinant vaccines against hepatitis B.
Martins RM; Bensabath G; Arraes LC; Oliveira Mde L; Miguel JC; Barbosa GG; Camacho LA
Mem Inst Oswaldo Cruz; 2004 Dec; 99(8):865-71. PubMed ID: 15761604
[TBL] [Abstract][Full Text] [Related]
5. Immunogenicity and reactogenicity of two recombinant hepatitis B vaccines in small infants: a randomized, double-blind comparative study.
Sapru A; Kulkarni PS; Bhave S; Bavdekar A; Naik SS; Pandit AN
J Trop Pediatr; 2007 Oct; 53(5):303-7. PubMed ID: 17478542
[TBL] [Abstract][Full Text] [Related]
6. Randomized comparison of 5 and 10 microgram doses of two recombinant hepatitis B vaccines.
Bryan JP; Craig PG; Reyes L; Hakre S; Jaramillo R; Harlan H; MacArthy P; Legters LJ
Vaccine; 1995 Aug; 13(11):978-82. PubMed ID: 8525691
[TBL] [Abstract][Full Text] [Related]
7. Immunogenicity, reactogenicity and safety of two-dose versus three-dose (standard care) hepatitis B immunisation of healthy adolescents aged 11-15 years: a randomised controlled trial.
Heron L; Selnikova O; Moiseieva A; Van Damme P; van der Wielen M; Levie K; Hoet B; Stoffel M
Vaccine; 2007 Apr; 25(15):2817-22. PubMed ID: 17276552
[TBL] [Abstract][Full Text] [Related]
8. Comparative efficacy, safety and immunogenicity of Hepavax-Gene and Engerix-B, recombinant hepatitis B vaccines, in infants born to HBsAg and HBeAg positive mothers in Vietnam: an assessment at 2 years.
Hieu NT; Kim KH; Janowicz Z; Timmermans I
Vaccine; 2002 Mar; 20(13-14):1803-8. PubMed ID: 11906768
[TBL] [Abstract][Full Text] [Related]
9. Comparative study of the immunogenicity and safety of Engerix-B administered at 0, 1, 2 and 12 months and Recombivax HB administered at 0, 1, and 6 months in healthy adults.
Rustgi VK; Schleupner CJ; Krause DS
Vaccine; 1995 Dec; 13(17):1665-8. PubMed ID: 8719517
[TBL] [Abstract][Full Text] [Related]
10. Comparison of two hepatitis B vaccines (GeneVac-B and Engerix-B) in healthy infants in India.
Shivananda ; Somani V; Srikanth BS; Mohan M; Kulkarni PS
Clin Vaccine Immunol; 2006 Jun; 13(6):661-4. PubMed ID: 16760324
[TBL] [Abstract][Full Text] [Related]
11. Comparison of four recombinant hepatitis B vaccines applied on an accelerated schedule in healthy adults.
Hernández-Bernal F; Aguilar-Betancourt A; Aljovin V; Arias G; Valenzuela C; de Alejo KP; Hernández K; Oquendo O; Figueredo N; Figueroa N; Musacchio A; Véliz G; García E; Mollineda AD; Juvier AI; Trujillo J; Delahanty A; Ortega D; Cinza Z; González VL
Hum Vaccin; 2011 Oct; 7(10):1026-36. PubMed ID: 21941089
[TBL] [Abstract][Full Text] [Related]
12. Immunogenicity of three recombinant hepatitis B vaccines administered to students in three doses containing half the antigen amount routinely used for adult vaccination.
Baldy JL; de Lima GZ; Morimoto HK; Reiche EM; Matsuo T; de Mattos ED; Sudan LC
Rev Inst Med Trop Sao Paulo; 2004; 46(2):103-7. PubMed ID: 15141282
[TBL] [Abstract][Full Text] [Related]
13. Immune response to an indigenously developed r-hepatitis B vaccine in mixed population: study of an accelerated vaccination schedule.
Chowdhury A; Santra A; Habibullah CM; Khan AA; Karunakaramaiah J; Kishore TS; Raju AV; Lahiri S
World J Gastroenterol; 2005 Feb; 11(7):1037-9. PubMed ID: 15742410
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of immunogenicity and reactogenicity of recombinant DNA hepatitis B vaccine produced in India.
Hussain Z; Ali SS; Husain SA; Raish M; Sharma DR; Kar P
World J Gastroenterol; 2005 Dec; 11(45):7165-8. PubMed ID: 16437665
[TBL] [Abstract][Full Text] [Related]
15. Comparative safety and immunogenicity of two recombinant hepatitis B vaccines given to infants at two, four and six months of age.
Greenberg DP; Vadheim CM; Wong VK; Marcy SM; Partridge S; Greene T; Chiu CY; Margolis HS; Ward JI
Pediatr Infect Dis J; 1996 Jul; 15(7):590-6. PubMed ID: 8823852
[TBL] [Abstract][Full Text] [Related]
16. Two-dose combined vaccination against hepatitis A and B in healthy subjects aged 11-18 years.
Van Herck K; Van Damme P; Collard F; Thoelen S
Scand J Gastroenterol; 1999 Dec; 34(12):1236-40. PubMed ID: 10636072
[TBL] [Abstract][Full Text] [Related]
17. Safety and immunogenicity of a modified process hepatitis B vaccine in healthy infants.
Vesikari T; Martin JC; Liss CL; Liska V; Schödel FP; Bhuyan PK
Pediatr Infect Dis J; 2011 Jul; 30(7):e109-13. PubMed ID: 21552183
[TBL] [Abstract][Full Text] [Related]
18. Immunogenicity of two paediatric doses of monovalent hepatitis B or combined hepatitis A and B vaccine in 8-10-year-old children.
Duval B; Gîlca V; Boulianne N; Deceuninck G; Rochette L; De Serres G
Vaccine; 2005 Jul; 23(31):4082-7. PubMed ID: 15963363
[TBL] [Abstract][Full Text] [Related]
19. Comparative study of the immunogenicity and safety of two doses of recombinant hepatitis B vaccine in healthy adolescents.
Schiff GM; Sherwood JR; Zeldis JB; Krause DS
J Adolesc Health; 1995 Jan; 16(1):12-7. PubMed ID: 7742331
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of the immunogenicity of a recombinant vaccine against hepatitis B containing S and pre-S2 sequences using two different schedules.
Gizaris V; Roumeliotou A; Ktenas E; Papoutsakis G; Papaevangelou G
Vaccine; 1993 Nov; 11(14):1445-7. PubMed ID: 8310765
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
